Ecabet (BioDeep_00000615046)

   


代谢物信息卡片


(1R,4aS,10aR)-1,4a-dimethyl-7-(propan-2-yl)-6-sulfo-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid

化学式: C20H28O5S (380.16573580000005)
中文名称: 依卡倍特
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)C1=C(C=C2C(=C1)CCC3C2(CCCC3(C)C(=O)O)C)S(=O)(=O)O
InChI: InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20-/m1/s1

描述信息

C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent
D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents
D020011 - Protective Agents > D016588 - Anticarcinogenic Agents
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
D000890 - Anti-Infective Agents
D000970 - Antineoplastic Agents

同义名列表

3 个代谢物同义名

(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-6-sulfo-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid; Ecabet; (1R,4aS,10aR)-1,4a-dimethyl-7-(propan-2-yl)-6-sulfo-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yongqing Wang, Nana Tang, Ling Meng, Peipei Zhang, Kun Xu, Ningling Jiang, Haibo Zhang, Ning Ou, Deqin Wu, Anjiu Chen, Xiyong Zhang, Ruihua Shi. Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects. Clinical drug investigation. 2012 Apr; 32(4):247-52. doi: 10.2165/11599110-000000000-00000. [PMID: 22299715]
  • Masumi Okuda, Noriyasu Yamamoto, Nobuhisa Fukuda, Kohei Maekawa, Takeshi Kusaka, Manabu Hashimoto, Junichiro Kotake, Hiromasa Koizuka, Yoshihiro Fukuda. Effect of ecabet sodium treatment on urea breath test and stool antigen tests in volunteers with Helicobacter pylori infection. Journal of gastroenterology and hepatology. 2012 Apr; 27 Suppl 3(?):100-2. doi: 10.1111/j.1440-1746.2012.07080.x. [PMID: 22486880]
  • Dan Zhang, Xiaolin Du, Mingyuan Liu, Hao Li, Yao Jiang, Limei Zhao, Jingkai Gu. Determination of ecabet in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 Mar; 863(2):223-8. doi: 10.1016/j.jchromb.2008.01.013. [PMID: 18258501]
  • Fumihiko Katagiri, Toru Shiga, Yuhki Sato, Shin Inoue, Hiroki Itoh, Masaharu Takeyama. Comparison of the effects of cytoprotective drugs on human plasma adrenocorticotropic hormone and cortisol levels with continual stress exposure. Biological & pharmaceutical bulletin. 2005 Nov; 28(11):2146-8. doi: 10.1248/bpb.28.2146. [PMID: 16272707]
  • Fumihiko Katagiri, Shin Inoue, Yuhki Sato, Hiroki Itoh, Masaharu Takeyama. Ecabet sodium raises plasma levels of calcitonin generelated peptide and substance P in healthy humans. The Journal of pharmacy and pharmacology. 2005 Jun; 57(6):799-805. doi: 10.1211/0022357056271. [PMID: 15969937]
  • Hiroyuki Taniguchi, Eiji Yomota, Koji Nogi, Yuichi Onoda. Effects of anti-ulcer agents on ethanol-induced gastric mucosal lesions in D-galactosamine-induced hepatitis rats. Arzneimittel-Forschung. 2002; 52(8):600-4. doi: 10.1055/s-0031-1299937. [PMID: 12236047]
  • Koji Nogi, Hiroyuki Taniguchi, Yuichi Onoda. Effects of the anti-ulcer agents ecabet sodium, cimetidine and sucralfate on acetylsalicylic acid-induced gastric mucosal damage deteriorated by renal failure in rats. Arzneimittel-Forschung. 2002; 52(11):828-32. doi: 10.1055/s-0031-1299975. [PMID: 12489254]
  • K Kawakami, M Yasuda, K Ishii, Y Kokusenya, T Sato. A kinetic study of protein binding to ecabet sodium using quartz-crystal microbalance. Chemical & pharmaceutical bulletin. 1999 Jul; 47(7):919-22. doi: 10.1248/cpb.47.919. [PMID: 10434394]
  • T Shimoyama, S Fukuda, M Tanaka, T Mikami, R Yamagata, T Yoshimura, Y Haga, Y Murata, A Munakata. Healing of cimetidine-resistant Ménétrier's disease by eradication of Helicobacter pylori infection. Journal of clinical gastroenterology. 1998 Dec; 27(4):348-50. doi: 10.1097/00004836-199812000-00015. [PMID: 9855268]
  • T Ohkusa, I Takashimizu, K Fujiki, S Suzuki, K Shimoi, T Horiuchi, T Sakurazawa, K Ariake, K Ishii, J Kumagai, T Tanizawa. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Annals of internal medicine. 1998 Nov; 129(9):712-5. doi: 10.7326/0003-4819-129-9-199811010-00006. [PMID: 9841603]
  • Y Ito, Y Onoda, S Nakamura, K Tagawa, T Fukushima, Y Sugawara, O Takaiti. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. II. Interaction with substrate protein. Japanese journal of pharmacology. 1993 Jun; 62(2):175-81. doi: 10.1254/jjp.62.175. [PMID: 8371516]
  • Y Ito, T Fukushima, Y Sugawara, O Takaiti, S Nakamura. Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)- 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1- methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). I. Disposition, metabolism and protein binding in rats and dogs. Journal of pharmacobio-dynamics. 1991 Sep; 14(9):533-46. doi: 10.1248/bpb1978.14.533. [PMID: 1779408]